icon-    folder.gif   Conference Reports for NATAP  
  22nd Conference on Retroviruses and
Opportunistic Infections
Seattle Washington Feb 23 - 26, 2015
Back grey_arrow_rt.gif
Effect of HIV Co-infection on Adherence to a 12-week regimen of HCV Therapy with Ledipasvir/Sofosbuvir
  Reported by jules Levin
CROI 2015
Feb 23-26, Seattle, WA
Kerry Townsend1,2, Tess Petersen3, Lori A. Gordon4, Amy Nelson1,2, Cassie Seamon3, Chloe Gross5, Anita Kohli3,5, Anu Osinusi2,3,6, Michael A. Polis1, Henry Masur3, Shyam Kottilil1,2
1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 2Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, 3Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA, 4Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD, USA 5Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical 18 Research, Inc. (formerly SAIC-Frederick, Inc), Frederick National Laboratory for Cancer Research, Frederick, MD, USA, 6Gilead Sciences Inc, Foster City, CA, USA.
AASLD/2014: ERADICATE Study: Use of Ledipasvir/Sofosbuvir Fixed Dose Combination for Treatment of HCV Genotype-1 Infection in Patients Coinfected with HIV
Combination Oral, Ribavirin Free, Antiviral Therapy to Optimize Treatment Outcomes for Hepatitis C Treatment Naïve Patients: Interim Results from the NIAID SYNERGY Trial (6 & 12 weeks therapy).....
SYNERGY published Jan